论文部分内容阅读
目的:观察泰素帝联合顺铂(DP方案)与长春瑞滨联合顺铂(NP方案)治疗晚期非小细胞肺癌的近期疗效、毒副反应。方法:70例晚期非小细胞肺癌患者随机分组,DP组34例,NP组36例,化疗2周期后评价疗效。结果:总有效率DP组41.2%,NP组36.1%,1年生存率DP组47.1%,NP组44.4%,两组比较均无显著性差异(P>0.05)。Ⅲ～Ⅳ度白细胞下降率DP组11.8%,NP组36.1%,有显著性差异(P<0.01);Ⅲ～Ⅳ度恶心、呕吐发生率DP组11.8%,NP组33.3%,有显著性差异(P<0.01)。结论:DP方案和NP方案治疗晚期NSCLC近期疗效肯定且相似,1年生存率相似,但DP组严重的骨髓抑制及严重的胃肠反应发生率均低于NP组,患者更易耐受DP化疗方案。
OBJECTIVE: To observe the short-term curative effect and toxicity of paclitaxel in combination with cisplatin (DP) and vinorelbine plus cisplatin (NP) in the treatment of advanced non-small cell lung cancer. Methods: Seventy patients with advanced non-small cell lung cancer were randomly divided into three groups: 34 in DP group and 36 in NP group. The efficacy was evaluated after 2 cycles of chemotherapy. Results: The total effective rate was 41.2% in DP group and 36.1% in NP group. The 1-year survival rate was 47.1% in DP group and 44.4% in NP group. There was no significant difference between the two groups (P> 0.05). Ⅲ ~ Ⅳ degree of leukopenia in the DP group was 11.8%, NP group 36.1%, there was a significant difference (P <0.01); Ⅲ ~ Ⅳ degree of nausea and vomiting incidence of DP group 11.8%, NP group 33.3%, a significant difference (P <0.01). Conclusions: The immediate and similar effects of DP regimen and NP regimen in the treatment of advanced NSCLC are similar and the 1-year survival rates are similar, but the severe myelosuppression and severe gastrointestinal reactions in DP group are lower than those in NP group. Patients are more likely to tolerate DP chemotherapy .